Epirus Biopharmaceuticals

company

About

Epirus Biopharmaceuticals develops biosimilar monoclonal antibodies and therapeutic proteins for emerging markets.

  • Boston,Massachusetts,United States
  • 51 - 100

Details

Last Funding Type
Series B
Last Funding Money Raised
$36M
Industries
Biotechnology,Life Science,Therapeutics
Founded date
Mar 28, 2000
Number Of Employee
51 - 100
Operating Status
Active
Stock Symbol
nasdaq:EPRSQ

EPIRUS is focusing on the central development of a broad pipeline of biosimilar monoclonal antibodies and therapeutic proteins, optimized for use within the SCALE™ disposable manufacturing system, and designed to be deployed in an "In Market, For Market" ™ manufacturing configuration.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
5
$83.08M
Epirus Biopharmaceuticals has raised a total of $83.08M in funding over 2 rounds. Their latest funding was raised on Jul 15, 2014 from a IPO round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jul 15, 2014 IPO Detail
Apr 16, 2014 Series B $36M 8 Livzon Mabpharm Detail
Jul 1, 2012 Series Unknown $5M 2 Detail
Apr 1, 2012 Series Unknown $8.08M 2 Detail
Jan 1, 2011 Series A $34M Detail

Investments

Number of Investments
Number of Lead Investments
1
0
Epirus Biopharmaceuticals has made 1 investments. Their most recent investment was on Dec 7, 2022, when Maergo raised $20M.
Date Company Name
Round Money Raised Industry Lead Investor
Dec 7, 2022 Maergo
Seed $20M E-Commerce

Investors

Number of Lead Investors
Number of Investors
1
8
Epirus Biopharmaceuticals is funded by 8 investors. Livzon Mabpharm and 5AM Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
Livzon Mabpharm Yes Series B
5AM Ventures Series B
Adage Capital Management Series B
Gibralt Capital Corporation Series B
Greenwoods Investment Series B
Montreux Equity Partners Series B
Mousse Partners Series B
TPG Biotech Series B

Employee Profiles

Number of Employee Profiles
8
Epirus Biopharmaceuticals has 8 current employee profiles, including Board member Daniel Turner
Board member
Board observer
Board member
Board member
Board member

Acquisition

Epirus Biopharmaceuticals has acquired 2 organizations. Their most recent acquisition was Zalicus on Jul 15, 2014. They acquired Zalicus for 0.

Date Company Name
Industry Acquisition Type Price
Jul 15, 2014 Zalicus
Biotechnology merge Detail
Sep 9, 2015 Bioceros
Biopharma acquisition $ 14.10M Detail